7. Drug updates |
Cannabis derived drug for type 2 diabetes
Findings from a randomized, double-blind, placebo-controlled phase 2a trial investigating two different phytocannabinoids in type 2 diabetes patients suggest that a nonpsychoactive analog of a cannabis component may represent a new agent for treating type 2 diabetes. Unlike the related — and better-known — cannabis constituent tetrahydrocannabinol (THC), cannabidiol (CBD) and tetrahydrocannabivarin (THCV) don't activate CB1receptors in the brain and therefore lack the psychotropic actions of THC.
A total 62 subjects with non–insulin-treated type 2 diabetes were randomized to one of five treatment arms: CBD (100 mg twice daily), THCV (5 mg twice daily), 1:1 ratio of CBD and THCV (5 mg/5 mg, twice daily), 20:1 ratio of CBD and THCV (100 mg/5 mg, twice daily), or matched placebo for 13 weeks. Fasting plasma glucose was lower with THCV from baseline compared with placebo, from about 133 mg/dL to 121 mg/dL (P < .05), along with a significant concurrent increase in beta-cell function (P < .01). Adverse events were reported by majorities of all groups, including placebo, and were mostly mild to moderate.
Semaglutide proven beneficial for heartSUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) is a clinical programme for semaglutide, administered once-weekly, that comprises six phase 3a global clinical trials encompassing more than 7,000 adults with type 2 diabetes as well as two Japanese trials encompassing around 1,000 adults with type 2 diabetes. Semaglutide is a once-weekly investigational analogue of human glucagon-like peptide-1 (GLP-1).
FDA APPROVES WORLD’S FIRST HYBRID CLOSED LOOP SYSTEMThe system delivers a variable rate of insulin 24 hours a day based on the personalized needs of the individual, maximizing the time glucose levels are within the target range.The system uses new Guardian Sensor 3, our most advanced and accurate glucose sensor which is the first and only sensor approved by the FDA to control a hybrid closed loop system.
FDA Approves FreeStyle LibrePro